Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.51 |
| ▸ | HTR3B | O95264 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1761029 | 0.94 | ALDH1A1 (0.72) | ALDH1A1KDM4EGAALMNACHRM3 | |
| Hydrochloric Acid SCHEMBL6734690 | 0.93 | ALDH1A1 (0.70) | ALDH1A1KDM4EGAALMNACHRM3 | |
| SCHEMBL4244138 | 0.87 | ALDH1A1 (0.97) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL4235961 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL30341002 | 0.85 | ALDH1A1 (1.00) | ALDH1A1KDM4EGAALMNAMEN1 | |
| SCHEMBL23632710 | 0.82 | CXCR4 (0.71) | ALDH1A1KDM4EGAACHRM3CXCR4 | |
| SCHEMBL674945 | 0.82 | CXCR4 (0.75) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL24322866 | 0.81 | ALDH1A1 (0.71) | ALDH1A1CHRM3CXCR4MEN1CHRM2 | |
| SCHEMBL675084 | 0.80 | CXCR4 (0.67) | ALDH1A1KDM4EGAACXCR4MEN1 | |
| SCHEMBL17929341 | 0.80 | CXCR4 (0.72) | ALDH1A1KDM4EGAACXCR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 2146/4885KDM4E 3572/4885GAA 4579/4885 |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | ALDH1A1 1491/4885KDM4E 3588/4885GAA 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.